Why did Amgen stock rise on 7 October?
Written after the close on
Amgen +2.60%
Amgen rose sharply on obesity-pipeline momentum. Over the last five trading days Amgen slipped slightly, moving against a clearly higher broad market while its healthcare peers were roughly flat, so the weekly drift looks more stock-specific than sector-driven. The likely driver of the latest session's sharp gain was renewed focus on Amgen's obesity pipeline and its once-quarterly dosing ambitions, alongside a late-stage immunology win that kept the name in the healthcare rotation. The earlier weakness likely reflected profit-taking and positioning ahead of the early-November earnings report, where analysts project modest earnings and revenue growth. Watch the obesity maintenance data and the upcoming report for confirmation.
Next report: · Add to calendar · Google Calendar